This 3-part series examines finerenone evidence from EASD 2026 across diverse populations with chronic kidney disease (CKD). Expert faculty discuss findings from INFINITY, FINE-ONE, and FIRST 2.5, including cardiovascular and kidney outcomes by baseline HbA1c, efficacy and safety by age in patients with CKD and type 1 diabetes, and real-world effectiveness in reducing urinary albumin-to-creatinine ratio (UACR) among patients in the US with CKD and type 2 diabetes. The series provides clinical context for interpreting these findings across patient characteristics, diabetes types, and research settings relevant to cardiorenal practice.